SEARCH

SEARCH BY CITATION

References

  • Aigner A., Jager M., Weber P., Wolf S. (1994) A nonradioactive assay for microsomal cysteine-S-conjugate N-acetyltransferase activity by high pressure liquid chromatography. Anal. Biochem. 223, 227231.DOI: 10.1006/abio.1994.1578
  • Baas H. (2000) Dyskinesia in Parkinson's disease. Pathophysiology and risk factors. J. Neurol. 247, IV/12IV/16.
  • Bachi M. & Ross-Petersen K. (1972) The step-wise removal of the Sp-nitrobenzyl protecting group. J. Org. Chem. 37, 35503551.
  • Baez S., Segura-Aguilar J., Widerstein M., Johansson A., Mannervik B. (1997) Glutathione transferases catalyse the detoxification of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degeneration cellular processes. Biochem. J. 324, 2528.
  • Berman S. & Hastings T. (1997) Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J. Neurochem. 69, 11851195.
  • Berman S., Zigmond M., Hastings T. (1996) Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 67, 593600.
  • Bolton J. L., Trush M. A., Penning T. M., Dryhurst G., Monks T. J. (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 141160.
  • Cairns J., Cattan A., Hall A., Cantwell B., Harris A., Horne C. (1992) Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J. Pathol. 166, 1925.
  • Campbell J., Corrigall A., Kirsch R. (1991) Immunohistologic localization of alpha, mu, and pi class glutathione S-transferases in human tissue. Cancer 67, 16081613.
  • Carder P., Hume R., Fryer A., Strange R., Lauder J., Bell J. (1990) Glutathione S-transferase in human brain. Neuropathol. Appl. Neurobiol. 16, 293303.
  • Clemens J. & Phebus L. (1988) Dopamine depletion protects striatal neurons from ischemia-induced cell death. Life Sci. 42, 707713.
  • Duffel M. & Jakoby W. (1982) Cysteine-S-conjugate N-acetyltransferase from rat kidney microsomes. Mol. Pharmacol. 21, 444448.
  • Eaton D. & Bammler T. (1999) Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol. Sci. 49, 156164.
  • Fleckenstein A., Gibb J., Hanson G. (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequnces and implications for neurotoxicity. Eur. J. Pharmacol. 406, 113.DOI: 10.1016/s0014-2999(00)00639-7
  • Fornstedt B. & Carlsson A. (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guinea pig striatum following reserpine treatment. J. Neural Transm. 76, 155161.
  • Fornstedt B. & Carlsson A. (1991) Vitamin C deficiency facilitates 5-S-cysteinydopamine formation in guinea pig striatum. J. Neurochem. 56, 407414.
  • Fornstedt B., Rosengren E., Carlsson A. (1986) Occurence and distribution of 5-S-cysteinyl derivitives of dopamine, dopa and dopac in th ebrains of eight mammalian species. Neuropharmacology 25, 451454.
  • Fornstedt B., Brun A., Rosengren E., Carlsson A. (1989) The apparent autooxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm. 1, 279295.
  • Fornstedt B., Pileblad E., Carlsson A. (1990) In vivo autooxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55, 655659.
  • Green R. & Elce J. (1975) Acetylation of s-substituted cysteines by a rat liver and kidney microsomal n-acetyltransferase. Biochem. J. 147, 283.
  • Grunblatt E., Mandel S., Youdim M. (2000) MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neurol. 247, 95102.
  • Hanigan M. & Frierson H. (1996) Immunohistochemical detection of γ-glutamyl transpeptidase in normal human tissue. J. Histochem. Cytochem. 44, 11011108.
  • Janowsky A., Neve K., Eshleman A. (1998) Uptake and release of neurotransmitters, in Current Protocols in Neuroscience (CrawleyJ. Gerfen C. McKay R. Rogawski M. Sibley D. and SkolnickP., eds), pp. 7.9.17.9.22. John Wiley and Sons, New York.
  • Jenner P., Dexter D., Sian J., Schapira A., Marsden C. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32, S82S87.
  • Johnson M., Stone D., Hanson G., Gibb J. (1987) Role of dopaminergic nigrostriatal pathway in metamphetamine-induced depression of the neostriatal serotonergic system. Eur. J. Pharmacol. 135, 231234.
  • Johnson J., Barbary A., Kornguth S., Brugge J., Siegel F. (1993) Glutathione S-tranferase isoenzymes in rat brain neurons and glia. J. Neurosci. 13, 20132023.
  • Li H., Shen X.-M., Dryhurst G. (1998) Brain mitochondria catalyze the oxidation of of 7-(2-aminoethyl)-3,4-dihydro-5–2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irrversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J. Neurochem. 71, 20492062.
  • Louis E., Klatka L. A., Liu Y., Fahn S. (1997) Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 48, 376380.
  • McKeith I. G., Galasko D., Kosaka K., Perry E. K., Dickson D. W., Hansen L. A., Salmon D. P., Lowe J., Mirra S. S., Byrne E. J., Lennox G., Quinn N. P., Edwardson J. A., Ince P. G., Bergeron C., Burns A., Miller B. L., Lovestone S., Collerton D., Jansen E. N., Ballard C., De Vos R. A., Wilcock G. K., Jellinger K. A., R. H. P. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 11131124.
  • Miller R., Lau S., Monks T. (1995) Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague–Dawley rats. Chem. Res. Toxicol. 8, 634641.
  • Montine T., Picklo M., Amarnath V., Whetsell W., Graham D. (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp. Neurol. 148, 2633.DOI: 10.1006/exnr.1997.6662
  • Neely M., Sidell K., Graham D., Montine T. (1999) The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J. Neurochem. 72, 23232333.
  • Parkinson A. (1996) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology (KlaassenC., ed.), pp.177183. McGraw-Hill, New York.
  • Paxinos G. & Watson C. (1997). The Rat Brain in Stereotaxic Coordinates, 3rd edn, Academic Press, San Diego, CA.
  • Picklo M., Amarnath V., Graham D., Montine T. (1999) Endogenous catechol thioethers may be pro-oxidant or antioxidant. Free Rad. Biol. Med. 27, 271277.
  • Ronald, Nancy Reagan Institute of the Alzheimer's Association and National Institute on Aging Working Group on Biological Markers of Alzheimer's Disease (1998) Consensus report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer’s Disease'. Neurobiol. Aging 19, 109116.
  • Rosengren E., Linder-Eliasson E., Carlsson A. (1985) Detection of 5-S-cysteinyldopamine in human brain. J. Neural Transm. 63, 247253.
  • Sandoval V., Riddle E., Ugarte Y., Hanson G., Fleckenstein A., (2001) Methmaphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J. Neurosci. 21, 14131419.
  • Schmidt C., Black C., Taylor V. (1990) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur. J. Pharmacol. 181, 5970.
  • Segura-Aguilar J., Baez S., Widersten M., Welch C., Mannervik B. (1997) Human classmuglutathione transferases, in particular isoenzymes M2–2, catalyze detoxification of the dopamine metabolite aminochrome. J. Biol. Chem. 272, 57275731.
  • Shen X.-M., Xia B., Wrona M., Dryhurst G. (1996) Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 11171126.
  • Sian J., Dexter D., Lees A., Daniel S., Jenner P., Marsden C. (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356361.
  • Spencer J., Jenner P., Daniel S., Lees A., Marsden D., Halliwell B. (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71, 21122122.
  • Weinberger J., Nieves-Rosa J., Cohen G. (1985) Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-para-tyrosine. Stroke 16, 864870.
  • Whitehead R., Ferrer J., Javitch J., Justice J. (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the dopamine transporter. J. Neurochem. 76, 12421251.
  • Yamaguchi T., Takei N., Araki K., Ishii K., Nagano T., Ichikawa T., Nawa H. (2000) Molecular characterizatiion of a novel gamma glutamyl transpeptidase homologue found in rat brain. J. Biochem. (Tokyo) 128, 101106.
  • Zeevalk G., Derr-Yellin E., Nicklas W. (1995) NMDA receptor involvement in toxicity to dopamine neurons caused by succinate dehydrogenase inhibitor 3-nitropropionic acid. J. Neurochem. 64, 455458.
  • Zhang F. & Dryhurst G. (1994) Effects of l-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37, 10841098.
  • Zhang J., Kravtsov V., Amarnath V., Picklo M., Graham D., Montine T. (2000) Enhancement of dopaminergic neurotoxicty by the mercapturate of dopamine: relevance to Parkinson's disease. J. Neurochem. 74, 970978.